The latest developments in autism research.
Next-generation trackers could realize a long-standing research dream: conducting sleep studies in large numbers of autistic people.
Scientists on social media this week discussed a failed attempt to replicate some functional MRI results and children’s journeys to an autism diagnosis in the United Kingdom.
Minimally verbal autistic preschoolers gained new words and phrases in a head-to-head comparison of two interventions.
This month’s issue of Going on Trial takes a sneak peek at some early null results from a small trial of a cannabidiol-based drug for autism, among other recent drug developments.
A potential threat to the integrity of data collected online and an analysis of the structure and function of dopamine receptors caught researchers’ attention on social media this week.
Autistic people tend to drop out of Medicaid once they reach adulthood in states that don’t waive the income restrictions on enrollment.
The drug clemastine and other compounds that fortify the protective sheath around neurons may prove therapeutic for some genetic neurodevelopmental conditions.
The paper marks the second retraction for one of the co-authors.
These scores — composite measures of a person’s autism-linked common genetic variants — cannot predict an autism diagnosis but could help researchers better understand the condition’s underlying biology.
The papers were flagged by a method that has now been called into question.
This week on social media, scientists discussed a new tool to quantify motion in 3D and responded to the announcement of the launch of Imaging Neuroscience.
